Dexamethasone
Dexamethasone sodium phosphate
Brand names:Decadron, Dexasone, Hexadrol
A long-acting synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive effects. Dexamethasone has broad applications in emergency medicine: airway swelling, anaphylaxis adjunct, croup, asthma exacerbation, increased intracranial pressure (cerebral edema from tumor or trauma), and adrenal insufficiency. Long half-life allows once-daily dosing for most indications.
Pharmacology and Actions
Binds to intracellular glucocorticoid receptors, translocates to the nucleus, and modifies gene transcription. Effects include suppression of inflammatory mediator production (cytokines, prostaglandins, leukotrienes), reduced vascular permeability, decreased leukocyte migration, immunosuppression, and increased gluconeogenesis. Approximately 25 times more potent than hydrocortisone with minimal mineralocorticoid activity. Long biological half-life (36 to 54 hours) supports daily or every-other-day dosing.
Indications
- Croup (mild to severe) in pediatric patients
- Severe asthma exacerbation
- Anaphylaxis adjunct (after epinephrine and antihistamines)
- Airway edema (post-extubation, angioedema)
- Increased intracranial pressure from cerebral edema (tumor, post-radiation)
- Bacterial meningitis adjunct (before or with first antibiotic dose)
- Adrenal insufficiency (replacement and stress dosing)
- Acute high-altitude cerebral edema (HACE) and severe acute mountain sickness
- Nausea and vomiting prophylaxis (chemotherapy, postoperative)
- Spinal cord compression
- COVID-19 with supplemental oxygen requirement
Absolute Contraindications
- Known hypersensitivity to dexamethasone or sulfites in some formulations
- Systemic fungal infection without concurrent antifungal therapy
- Live virus vaccination during therapy (relative contraindication)
Precautions and Side Effects
Hyperglycemia (rapid onset, especially in diabetics). Hypertension. Mood changes including euphoria, insomnia, agitation, occasionally psychosis. Immunosuppression with prolonged use. Gastrointestinal ulceration. Adrenal suppression with courses longer than 5 to 7 days requiring taper. Osteoporosis and avascular necrosis with chronic use. Perineal burning with rapid IV push. Wound healing impairment. Fluid retention less than with hydrocortisone due to minimal mineralocorticoid effect.
Adult Dosing
Pediatric Dosing
Croup: 0.6 mg/kg PO/IV/IM single dose (max 10 to 16 mg). Asthma: 0.6 mg/kg PO/IV (max 16 mg) daily for 1 to 5 days. Anaphylaxis adjunct: 0.6 mg/kg IV/IM. Bacterial meningitis: 0.15 mg/kg IV every 6 hours for 4 days, before or with first antibiotic.
Pharmacokinetics
Peak Effect: 1 to 2 hours IV; clinical anti-inflammatory effect peaks at 4 to 24 hours
Duration: Biological half-life 36 to 54 hours; clinical effect 24 to 72 hours per dose
Storage and Handling
Room temperature 15 to 30 degrees C; protect from light. IV/IM preparations typically 4 mg/mL or 10 mg/mL; tablets 0.5 to 6 mg. Shelf life 18 to 36 months. Crystallization may occur with cold storage; warm to room temperature before use if observed.
Reconstitution:
Pre-filled vials at 4 mg/mL or 10 mg/mL ready to use IV/IM. May dilute in 50 to 100 mL D5W or NS for slower infusion. PO tablets dissolved or given whole; pediatric dosing often uses the IV formulation given orally (acceptable bioavailability).
TCCC and TECC Role
Not in core TCCC formulary but referenced in TCCC and TECC for specific applications: airway edema after burn or smoke inhalation, anaphylaxis adjunct, high-altitude cerebral edema in mountain or aviation environments. CMC and CPP providers may administer dexamethasone in prolonged casualty care for airway swelling, sepsis adjunct in specific scenarios, and adrenal insufficiency.
Dexamethasone is one of the most versatile drugs in tactical and emergency medicine. The single-dose protocol for croup keeps pediatric patients out of the hospital. The asthma exacerbation dose prevents bounce-back ED visits. The HACE dose at high altitude can be the difference between evacuation and walking out. The cerebral edema indication remains important for traumatic brain injury with mass effect from contusion, hematoma, or tumor (though TCCC 2026 emphasizes hypertonic saline for acute herniation rather than dexamethasone). The COVID-19 indication (6 mg once daily) emerged from the RECOVERY trial and remains standard of care for hypoxic COVID. The long half-life is operationally useful: once daily dosing simplifies prolonged casualty care.
Using dexamethasone for acute traumatic intracranial hypertension. TCCC 2026 and modern neurocritical care use hypertonic saline (3% or 23.4%) for acute herniation, not steroids. Dexamethasone has a role in vasogenic edema from tumor or radiation; it does not help acute traumatic cerebral edema in the time frame that matters. The other common mistake is using dexamethasone as a sole therapy for anaphylaxis; epinephrine is first-line and life-saving, dexamethasone is an adjunct that may prevent biphasic reactions.
This drug profile is provided as educational reference material for trained medical providers. It is not medical advice, not a substitute for formal training, and not a substitute for current published guidelines or medical direction.
Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances are subject to additional handling, accountability, and documentation requirements per DEA and state law. Always verify dosing, indications, contraindications, and route of administration against current published guidelines and your local protocols before administration.
If this content is being viewed during a medical emergency, call 911 immediately and follow the direction of your local emergency dispatch and medical control. Do not use this reference as a substitute for emergency medical services.
Drug information evolves. Last reviewed dates and source citations are provided for each entry. Confirm currency against the cited source before clinical use.
Penn Tactical Solutions publishes this reference for educational purposes. PTS does not provide medical direction and does not assume responsibility for clinical decisions made in the field. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Educational reference for trained medical providers. Not medical advice. Not a substitute for formal training, current published guidelines, or medical direction. Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances require additional storage, accountability, and documentation per DEA and state law.
In a medical emergency, call 911. This reference is not a substitute for emergency medical services.
Verify dosing, indications, and contraindications against current published guidelines and your local protocols before administration. Confirm content currency against the source citation. Penn Tactical Solutions does not provide medical direction. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Dexamethasone
| IV/IO | Variable by indication: Croup adjunct or asthma: 0.6 mg/kg (max 10 to 16 mg) IV/IM/PO once. Anaphylaxis adjunct: 10 mg IV/IM. Cerebral edema: 10 mg IV loading, then 4 mg IV every 6 hours. Spinal cord compression: 10 mg IV initial, then 4 mg every 6 hours. HACE: 8 mg IV/IM initial, then 4 mg every 6 hours. COVID-19: 6 mg IV/PO once daily for 10 days. Bacterial meningitis: 10 mg IV every 6 hours before or with first antibiotic, continued for 4 days. (Within minutes (anti-inflammatory effect peaks over hours)) |
| IM | Same doses as IV (IM bioequivalent for most indications). (1 to 2 hours) |
| IN | None (None) |
| PO | Equivalent to IV/IM in most indications: 6 to 10 mg PO daily; croup pediatric dosing also valid PO; tablet doses 0.5 to 6 mg available. (30 to 60 minutes (extended absorption)) |